192 related articles for article (PubMed ID: 12759581)
1. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.
Rasche FM; Klotz CH; Czock D; Karges W; Muche R; Jehle PM; Mertz A; Keller F
Nephron Clin Pract; 2003; 93(4):c131-6. PubMed ID: 12759581
[TBL] [Abstract][Full Text] [Related]
2. Sequential immunosuppressive therapy in progressive IgA nephropathy.
Rasche FM; Keller F; von Müller L; Czock D; Lepper PM
Contrib Nephrol; 2007; 157():109-13. PubMed ID: 17495446
[TBL] [Abstract][Full Text] [Related]
3. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide.
Tumlin JA; Lohavichan V; Hennigar R
Nephrol Dial Transplant; 2003 Jul; 18(7):1321-9. PubMed ID: 12808169
[TBL] [Abstract][Full Text] [Related]
4. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
5. The effects of cytotoxic therapy in progressive IgA nephropathy.
Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
[TBL] [Abstract][Full Text] [Related]
6. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.
Mitsuiki K; Harada A; Okura T; Higaki J
Clin Exp Nephrol; 2007 Dec; 11(4):297-303. PubMed ID: 18085391
[TBL] [Abstract][Full Text] [Related]
7. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
McIntyre CW; Fluck RJ; Lambie SH
Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
[TBL] [Abstract][Full Text] [Related]
8. Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.
Rasche FM; Keller F; Rasche WG; Schiekofer S; Kahn T; Fahnert J
Clin Exp Immunol; 2016 Feb; 183(2):307-16. PubMed ID: 26439797
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.
Tumlin JA; Hennigar RA
Semin Nephrol; 2004 May; 24(3):256-68. PubMed ID: 15156530
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy.
Rasche FM; Keller F; von Müller L; Sailer LK; Karges W; Czock D
J Nephrol; 2006; 19(4):465-72. PubMed ID: 17048204
[TBL] [Abstract][Full Text] [Related]
11. Prospective trial of combined therapy with heparin/warfarin and renin-angiotensin system inhibitors in progressive IgA nephropathy.
Ishii T; Kawamura T; Tsuboi N; Ogura M; Utsunomiya Y; Hosoya T
Contrib Nephrol; 2007; 157():114-9. PubMed ID: 17495447
[TBL] [Abstract][Full Text] [Related]
12. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.
Ballardie FW; Roberts ISD
J Am Soc Nephrol; 2002 Jan; 13(1):142-148. PubMed ID: 11752031
[TBL] [Abstract][Full Text] [Related]
13. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
14. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
15. Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone.
Hwang YC; Lee TW; Kim MJ; Yang MH; Ihm CG
Korean J Intern Med; 2001 Jun; 16(2):105-9. PubMed ID: 11590896
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function.
Tamura S; Ueki K; Ideura H; Tsukada Y; Maezawa A; Kawai H; Wakamatsu R; Yano S; Nojima Y; Naruse T
Clin Nephrol; 2001 Mar; 55(3):192-5. PubMed ID: 11316238
[TBL] [Abstract][Full Text] [Related]
17. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
[TBL] [Abstract][Full Text] [Related]
18. Combination of pulse cyclophosphamide and steroids in crescentic IgA nephropathy.
Ramachandran R; Doddi P; Nandakrishna B; Nada R; Kumar V; Rathi M; Kohli HS; Jha V; Sakhuja V; Gupta KL
Int Urol Nephrol; 2015 Nov; 47(11):1917-8. PubMed ID: 26411427
[No Abstract] [Full Text] [Related]
19. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[TBL] [Abstract][Full Text] [Related]
20. Advanced IgA nephropathy: to treat or not to treat?
Locatelli F; Pozzi M; Del Vecchio L; Pozzi C
Nephron Clin Pract; 2003; 93(4):c119-21. PubMed ID: 12759578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
